Key Highlights
- Collaboration Revenue was USD 2.18 million in the third quarter, down from USD 8.66 million a year earlier, as income from the Ionis agreement fell to USD 2.18 million from USD 8.53 million.
- The net loss was USD 21.1 million versus USD 20.4 million in the prior-year quarter, while operating expenses dropped to USD 24.4 million from USD 31.5 million.
- Cash, cash equivalents and marketable securities stood at USD 101.7 million on September 30, 2026, which management expects to fund operations for at least 12 months from the filing date.
- The FDA cleared the investigational new drug application for MGX-001 in November 2026, with a Phase 1/2 hemophilia A trial planned to start in the first half of 2027.
Ionis Revenue Fade Leaves Third-Quarter Sales at USD 2.18 Million
Metagenomi Therapeutics (NASDAQ:MGX) filed its Quarterly Report for the period ended September 30, 2026 on November 10, 2026. Collaboration revenue, its only revenue line, fell USD 6.5 million to USD 2.18 million, with USD 6.4 million of the drop tied to the Ionis agreement. Nine-month revenue was USD 3.18 million against USD 21.30 million, with a USD 2.6 million cumulative catch-up adjustment from adding new research services for one target. Research and Development expense fell to USD 17.5 million from USD 25.3 million, while general and administrative expense rose to USD 6.9 million, including USD 1.2 million of net litigation settlement expense. The operating loss narrowed to USD 22.2 million from USD 22.8 million, but lower interest income of USD 1.05 million against USD 2.21 million left the net loss wider.
FDA Clears MGX-001 and Sets a 2027 Clinical Timetable
The company is an in vivo genome editing Business built on CRISPR tools found through metagenomics. Its lead program, MGX-001, is a one-time treatment for hemophilia A that uses a viral vector to deliver a Factor VIII gene and a lipid nanoparticle to deliver the editing instructions, inserting the gene into albumin so the liver makes the clotting protein. It submitted the application in October 2026, and the FDA cleared it in November 2026. The INTEGR8 study is planned as a global, open-label dose-escalation trial in adults with moderately severe to severe disease, starting in the first half of 2027 with first clinical data in the second half of 2027. Additional preclinical results are due in an oral presentation at the American Society of Hematology meeting on December 14, 2026 in New Orleans.
Cash Cushion, Accumulated Deficit and an Unused Share Program
Operating cash use over nine months was USD 59.8 million, down from USD 65.3 million, and the nine-month net loss was USD 71.7 million compared with USD 65.3 million. The filing says the USD 101.7 million of Liquidity should cover at least 12 months, but it also warns that the plan could change and funding may be needed sooner. An at-the-market program allows sales of up to USD 75.0 million of stock, which would dilute existing holders if used, and no shares had been sold under it by September 30, 2026. It has no product revenue, and the four cardiometabolic targets in the first wave of the Ionis collaboration remain in lead optimization.
Where Things Stand
Revenue fell mainly because Ionis collaboration income shrank, and the FDA clearance does not change that near-term line. Metagenomi Therapeutics (NASDAQ:MGX) paired a USD 21.1 million quarterly net loss with a sharply lower cost base and USD 101.7 million of liquidity, while the regulatory step moves MGX-001 toward a first trial. Next markers are the December 14 presentation, trial start in the first half of 2027 and first clinical data in the second half.


_11_20_2026_14_55_23_118425.jpg)



Please wait processing your request...